New research reveals a lack of consensus in defining moderate Crohn’s disease and ulcerative colitis, limiting optimal ...
AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Moderate-to-severe disability affects nearly one-third of patients with inflammatory bowel disease, according to a recent review.
Spyre Therapeutics Inc. SYRE shares are up on Monday following the announcement of positive results from the Phase 2 SKYLINE ...
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...
-PK/PD confirm results seen in healthy volunteer studies, with median RO >99% and saturation achieved early and sustained at week 12- WALTHAM, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Morphic ...
Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...
Moderate-to-severe disability affects nearly one-third of patients with inflammatory bowel disease (IBD), according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results